ADC Therapeutics SA Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed this Form 6-K for April 2021 on April 14, 2021. The filing concerns the company’s invitation and proxy materials for its annual general meeting, rather than operating or financial results.
The annual general meeting was expected to occur on June 10, 2021, at the company’s headquarters in Epalinges, Switzerland.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial performance metrics.
Material changes versus the prior comparable period
No financial or operational changes versus a prior period are disclosed.
Governance, risks, and unusual items
- Because of the COVID-19 pandemic and applicable Swiss COVID-19 regulations, shareholders were not permitted to attend the annual general meeting physically.
- Shareholders could exercise voting rights only by submitting voting instructions to the independent proxy in accordance with the meeting invitation and proxy materials.
- The filing included the invitation, shareholder meeting notice, and proxy cards for record holders and brokers.
Important facts for investors to verify
- Confirm the final date, time, format, and voting procedures for the annual general meeting.
- Review the accompanying invitation, shareholder meeting notice, and proxy materials for proposed resolutions and voting deadlines.
- Use the company’s annual report or other SEC filings to assess financial performance, liquidity, debt, and business outlook, as those matters are not addressed in this Form 6-K.